Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer | |
Blackhall Fiona; Ross Camidge D; Shaw Alice T; Soria Jean-Charles; Solomon Benjamin J; Mok Tony; Hirsh Vera; Jänne Pasi A; Shi Yuankai; Yang Pan-Chyr | |
2017 | |
卷号 | 2期号:3页码:e000219 |
关键词 | Alk clinical trial crizotinib profile 1005 |
ISSN号 | 2059-7029 |
DOI | 10.1136/esmoopen-2017-000219 |
URL标识 | 查看原文 |
收录类别 | PUBMED |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6362191 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Blackhall Fiona,Ross Camidge D,Shaw Alice T,et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer[J],2017,2(3):e000219. |
APA | Blackhall Fiona.,Ross Camidge D.,Shaw Alice T.,Soria Jean-Charles.,Solomon Benjamin J.,...&Kim Dong-Wan.(2017).Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.,2(3),e000219. |
MLA | Blackhall Fiona,et al."Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer".2.3(2017):e000219. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论